RXi Pharmaceuticals exercised its option to acquire an exclusive, worldwide license to Advirna’s RNAi delivery technology. The technologies licensed from Advirna encompass four approaches, focused primarily on self-delivery of RNAi therapeutics.
Advirna’s technology has been integrated into RXi’s rxRNA™ platform to generate so-called self-delivering rxRNAs (sd-rxRNAs), which the company maintains require no separate delivery vehicle such as liposomes, complexes, or nanoparticles. Additional advantages of the new sd-rxRNAs are reported to include their spontaneous cellular uptake, patient-friendly (subcutaneous) administration, tissue-targeted biodistribution/reduced renal clearance, and reduced side-effects.
“The ability to create self-delivering RNAi therapeutics promises to provide significant competitive advantages in efficacy, toxicity, ease of administration, and manufacturing costs,” states RXi president and CEO, Tod Woolf, Ph.D.